Interestingly, the survival of EML4-ALK v3-driven H2228 cells was consistently better than that of EML4-ALK v1-driven H3122 cells before and after the addition of fibroblasts, which is consistent with the worse outcomes observed for v3-driven ALK + NSCLC in clinical practice [63]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.